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Abstract
Background: Study of ERK activation has thus far relied on biochemical assays that are limited to
the use of phospho-specific antibodies and radioactivity in vitro, and analysis of whole cell
populations in vivo. As with many systems, fluorescence resonance energy transfer (FRET) can be
utilized to make highly sensitive detectors of molecular activity. Here we introduce FRET-based
ERK Activity Sensors, which utilize variants of Enhanced Green Fluorescent Protein fused by an
ERK-specific peptide linker to detect ERK2 activity.
Results: ERK Activity Sensors display varying changes in FRET upon phosphorylation by active
ERK2 in vitro depending on the composition of ERK-specific peptide linker sequences derived from
known in vivo ERK targets, Ets1 and Elk1. Analysis of point mutations reveals specific residues
involved in ERK binding and phosphorylation of ERK Activity Sensor 3. ERK2 also shows high in
vitro specificity for these sensors over two other major MAP Kinases, p38 and pSAPK/JNK.
Conclusion: EAS's are a convenient, non-radioactive alternative to study ERK dynamics in vitro.
They can be utilized to study ERK activity in real-time. This new technology can be applied to
studying ERK kinetics in vitro, analysis of ERK activity in whole cell extracts, and high-throughput
screening technologies.
Background
Traditional methods for studying signal transduction cas-
cades have been based solely on biochemical analysis of
whole cell populations and homogenized tissues (e.g.
radioassays, western blots, etc.). In addition, in vitro stud-
ies have required the use of radioactive isotopes for bio-
chemical characterization of kinases. These methods are
time consuming, produce large quantities of radioactive
waste, and do not allow for the study of real-time kinase
dynamics.
Recently, sensors for studying signal molecules in vitro, as
well as cascade dynamics in single cells, have been devel-
oped utilizing fluorescent proteins and the phenomenon
of fluorescence resonance energy transfer (FRET). FRET is
a phenomenon by which energy is transferred from one
fluorescent molecule to another by way of dipole-dipole
interactions during excitation of the donor molecule.
FRET efficiency is given by the equation:
where R is the donor-acceptor radius and Ro is the radius
at which FRET efficiency is 50% (Förster radius). Small
changes in R (1–2Å) and small orientation changes
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matically affect the efficiency of FRET, making very small
changes in structure easily detectable. The limitation,
however, is that FRET is effective only between 10–100Å,
and therefore the donor and acceptor must be maintained
in close proximity. Genetically encoded fluorescent pro-
teins fused by linker peptide sequences have been utilized
to address proximity limitations, as well as facilitate the
delivery of the sensor into live cells.
Some of the earliest work done with these sensors
includes genetically encoded sensors of caspase activity, in
which caspase-3 and caspase-8 sensitive linker peptides
were fused between the different variants of Enhanced
Green Fluorescent Protein (EGFP) [1]. These studies
allowed the characterization of apoptosis in single living
cells with spatio-temporal resolution. Other types of FRET
signaling sensors have since evolved, including sensors for
calcium signaling [2], receptor tyrosine kinases [3,4],
intracellular kinases [4-7], and histone methylation [8].
These sensors have been shown to be useful in in vitro
assays, as well as allow the study of signaling events in a
single cell, in real time [4].
The Ras/ERK cascade controls differentiation and prolifer-
ation in many different cell types and organisms. In this
signal transduction pathway, activated Ras (Ras-GTP)
binds directly to Raf-1 and recruits it to the membrane
where Raf becomes activated. Raf then phosphorylates
and activates Mek-1 and Mek-2 (the MAPK kinase), which
in turn phosphorylate the MAPKs ERK-1 and ERK-2. Acti-
vated ERKs translocate to the nucleus and directly phos-
phorylate transcriptional regulatory proteins (including
members of the Ets family of transcription factors, and the
bZIP factors Fos and Jun) (reviewed in [9]). Kinetics and
in vivo dynamics of ERK MAP kinase activity are not com-
pletely understood. Traditionally, the level of ERK activa-
tion has been thought to be relative to the strength of the
upstream signal. Some data suggest, however, that ERK
activation is "switch-like," requiring a threshold of activa-
tion, above which all ERK molecules within the cell
become activated [10]. Computational models of MAPK
signaling mechanisms can fit both possibilities [11,12].
Therefore, the development of new tools to study these
dynamics is essential to determine the biochemical nature
of ERK signaling.
In this manuscript, we describe the development of sev-
eral FRET-based sensors of MAP kinase activity which we
have called ERK Activity Sensors (EAS). Peptide linker
sequences taken from the Ets family transcription family
members Ets1 and Elk1, both ERK targets, were fused
between cyan and yellow variants of EGFP (ECFP and
EYFP, respectively). Several of our constructs respond to
phosphorylation by activated ERK with changes in FRET,
and at least one of them, EAS-3, is specific for active Extra-
cellular Regulated Kinase (ERK) as opposed to two other
MAP kinases, p38 and SAPK/JNK. Therefore, EAS-3 is a
viable, non-radioactive sensor of ERK MAPK activity in
vitro.
Results and discussion
Design and model of EAS
EAS was designed to have a short peptide linker sequence
sensitive to phosphorylation by ERK fused between ECFP
and EYFP. ECFP and EYFP were chosen as a FRET pair
because of the good spectral overlap between the emis-
sion of ECFP and the excitation of EYFP. We hypothesized
that phosphorylation would result in changes in second-
ary structure of the linker peptide that would alter FRET
efficiency for the protein (Figure 1A). Since it was unclear
which factors would contribute to forming a suitable
FRET sensor, we prepared several different constructs with
peptide linker sequences containing ERK phosphoryla-
tion sites taken from Ets1 and Elk1 transcription factors,
which are physiological substrates of the ERK MAPKs (Fig-
ure 1B). EAS-2, derived from mouse Ets1, has a rather
large linker peptide, due to the discovery that the MAP
Kinase binding site (D-domain) is approximately 90
amino acids downstream of the target serine [13]. The
linker sequences for EAS 3–5 were taken from human
Elk1, which has been shown to have the DEF domain
(FXFP amino-acid motif), a known MAPK binding site,
near the C-terminus. These peptides also contain two Ser-
ine-Proline (SP) motifs (consensus MAPK phosphoryla-
tion sites) corresponding to serines 383 and 389 of Elk1,
which have been shown to be targets of MAP kinases.
Phosphorylation of these serines has also been shown to
be directed specifically by the DEF domain [14]. EAS-Neg
is a negative control construct with a short peptide linker
derived from Ets1, containing a consensus MAPK phos-
phorylation site, but no MAPK binding site.
EAS FRET changes in the presence of active ERK2
We expected a change in energy transfer between ECFP
and EYFP upon incubation with active ERK2 (pERK2) for
EAS to be effective as a real time sensor. This would indi-
cate that a phosphorylation event had affected the dis-
tance and orientation between the two fluorophores. Each
EAS construct was incubated with pERK2 in a fluorimeter
(30°C) and readings were taken prior to addition of ATP.
Upon the addition of ATP, all EAS constructs, with the
exception of EAS-Neg, showed a decrease of energy trans-
fer indicated by an increase in donor (ECFP) emission
(475 nm) with a concomitant decrease in acceptor (EYFP)
emission (525 nm) after 40 minutes (Figure 2A). There-
fore, a decrease in FRET efficiency correlates with phos-
phorylation of EAS by pERK2. The resultant change in
ECFP/EYFP emission ratio is comparable to or exceeds
that of similar FRET-based signal transduction sensors [4-Page 2 of 8
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BMC Chemical Biology 2005, 5:1 http://www.biomedcentral.com/1472-6769/5/1A model for EAS activation and construct designFigure 1
A model for EAS activation and construct design. (A) Our inferred model indicates that upon pERK2 phosphorylation a 
conformational change in the linker peptide of EAS decreases the efficiency of FRET. The red area in the linker peptide indi-
cates the relative position of either D-domain (EAS-2) or DEF domain (EAS-3, -4, -5) and the SP motifs denote the consensus 
phosphorylation sites. (B) The gene constructs include EAS-Neg and EAS-2, which are derived from mouse Ets1. EAS 3–5 con-
tain peptide linkers derived from human Elk1. The composition of each linker peptide is indicated by the primary sequence 
positions derived from Ets1 and Elk1, respectively.
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change in FRET over the course of 30 minutes, confirming
the specificity of ERK2 for EAS 2–5 and the requirement of
a phosphorylation event to induce a change in FRET. Fig-
ure 2B shows the absolute change in ECFP/EYFP ratio over
a 40 minute time course for each construct. EAS-3 and
EAS-4 show the greatest absolute decrease in EYFP/ECFP
emission ratio, with EAS-5 having an intermediate change
in emission ratio. EAS-2 showed very little change in
FRET. Phosphorylation was also confirmed by an in vitro
kinase 32P phosphorylation assay using recombinant
pERK2 (Figure 2C). EAS 2–5 sensors were efficiently phos-
phorylated as compared to the non-specific control, EAS-
Neg, and Myelin Basic Protein (MBP), a common target of
activated MAPKs for in vitro studies. Based on the robust
FRET signal change and radioassay results, further studies
focused on EAS-3.
EAS changes in FRET in response to pERK2 require 
phosphorylation and the ERK binding site
Mutants of EAS-3 were utilized to validate the structural
features of EAS essential for decreased FRET efficiency
EAS proteins are targets for ERK2 and exhibit decreased FRETefficiency upon phosphorylationFigure 2
EAS proteins are targets for ERK2 and exhibit decreased FRETefficiency upon phosphorylation. (A) Emission 
spectra indicate the effective FRET change for each EAS protein sensor. Time course fluorimetry with EAS-Neg shows that 
pERK2 induces no FRET change 30 minutes after ATP addition. All other EAS proteins show varying gains in ECFP emission 
(475 nm) and losses in EYFP emission (525 nm) 40 minutes after ATP addition. (B) Absolute change in the ratio of EYFP/ECFP 
emission for EAS-Neg is zero over a 30 minute time course, whereas a decrease in ratio for EAS-3, EAS-4, and EAS-5 is readily 
detectable at 2 minutes, and continues to decay exponentially over the time course. EAS-2 has a detectable change in emission 
ratio, but the change is minimal as compared to other EAS proteins. Error analysis was determined from three independent 
experiments. (C) EAS proteins (EAS-2, -3, -4, and -5) are phosphorylated by pERK2 in the presence of γ-[32P]ATP. This con-
firms that EAS proteins are targets of pERK2 as compared with MBP, a known ERK2 substrate. As expected, EAS-Neg is not 
phosphorylated by pERK2.
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BMC Chemical Biology 2005, 5:1 http://www.biomedcentral.com/1472-6769/5/1upon incubation with pERK2. We refined EAS-3 by replac-
ing the bulky N-terminal GST-purification tag
(Glutathione-S-Transferase) with a Histidine-10 tag on
the C-terminus. This reduced the possibility that the large
purification tag would interfere with FRET efficiency
changes. In addition, we mutated alanine 207 and alanine
487 to lysine. As previously reported, this prevents EGFP
dimerization [15]. This latter modification reduced co-
purification of truncation products with full-length EAS
(data not shown).
To further characterize EAS-3, we generated different con-
structs targeting critical residues, and analyzed their abil-
ity to serve as substrates for pERK2. Mutants EAS3-S286A,
EAS3-S292A, and the double mutant EAS3-S(286,292)A
eliminated consensus phosphorylation sites (Figure 2A).
The dead binding domain mutant (EAS3-DBD) elimi-
nated the DEF domain by replacing the two key phenyla-
lanines with alanines, creating an AXAP motif (Figure 3A).
As Figure 3B demonstrates, all five mutants have
decreased phosphorylation compared to the wild type
sensor. As expected, the EAS3-S(286,292)A mutant had
the lowest level of phosphate incorporation due to
absence of both serine-proline consensus phosphoryla-
tion sites required by MAP Kinases. A decrease in phos-
phorylation of EAS-DBD iss also consistent with the
requirement of MAPKs to bind targets for efficient phos-
phorylation (reviewed in [16]). Differences between wild-
type EAS-3 and mutants are also reflected in change of
FRET efficiency when treated with pERK2 in fluorimeter
experiments (Figure 3C). These relative changes in FRET
efficiency are consistent with the radioassay data.
EAS-3 is not phosphorylated by pSAPK or pp38
Distinguishing the activation of different MAP kinases
within the cell is essential since each MAPK pathway is
activated by multiple mitogens and external environmen-
tal factors to varying degrees (reviewed in [17]). Further-
more, there is extensive cross-talk between the different
MAP kinase pathways. Detection methods must effec-
tively isolate the signal of the target kinase from other
family members to elucidate the contributions of these
different pathways to a given cellular process.
The target peptide linkers were designed to impart specif-
icity for ERK. Elk1 and Ets1 were chosen because of their
seemingly specific interaction with ERK relative to p38 or
SAPK/JNK (reviewed in [18]). To determine whether EAS-
3 acted as a specific substrate for ERK we performed in
vitro phosphorylation assays to quantify the ability of
pERK2, pp38, and pSAPK/JNK to phosphorylate EAS-3
(Figure 4). As shown in Figure 4A, EAS-3 is an approxi-
mately 2000-fold more specific target for pERK2 than
pp38, and 50-fold more specific for pERK2 than pSAPK/
JNK. Activities of pERK2, pp38 and pSAPK/JNK were
Mutation of key residues diminishes EAS-3 phosphorylation by pERK2Figure 3
Mutation of key residues diminishes EAS-3 phosphor-
ylation by pERK2. (A) Primary sequences of EAS-3 and 
EAS-3 mutant linker peptides are shown with consensus 
phosphorylation sites (highlighted in green) and ERK binding 
sites (underlined). Residue mutations to alanine are high-
lighted in red. (B) Analysis of mutant EAS-3 proteins by γ-
[32P]ATP phosphorylation shows complete loss of pERK2 
phosphorylation of the S(286,292)A mutant as compared to 
wild-type EAS-3. Decreased 32P-phosphorylation of site-spe-
cific mutants also indicates the involvement of both Ser286 
and Ser292 for pERK2 activity. Requirement of the ERK bind-
ing domain for efficient phosphorylation is evident from 
decreased phosphorylation of the EAS3-DBD mutant. Band 
intensities were quantitated by densitometry and are shown 
graphically. Equal protein loading is shown by Coomassie 
staining of EAS-3 and EAS-3 mutants and phosphorylation 
assay was terminated after 15 minutes at 30°C. (C) Fluorime-
try data for EAS-3 and EAS-3 mutants reveals that the FRET 
efficiency change is reduced with various mutations, consist-
ent with the phosphorylation assay in B.
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BMC Chemical Biology 2005, 5:1 http://www.biomedcentral.com/1472-6769/5/1confirmed by using known substrates specific for each
kinase (Figure 4B). MBP was used in conjuction with
pERK2, GST-ATF2 with pp38, and GST-c-Jun with pSAPK/
JNK. Specificity of these kinases for EAS-3 was also con-
firmed by FRET in a fluorimeter (Figure 4C). It is clear that
the change in FRET was dramatic when EAS-3 was incu-
bated with pERK2, but showed little or no response when
incubated with pp38 or pSAPK/JNK. This is consistent
with the results found in 4A. Given the similarity of these
kinases, this also suggests that EAS-3 would be specifically
acted upon by pERK2 even in the presence of other acti-
vated intracellular kinases.
The demonstrated specificity of pERK2 for EAS-3 phos-
phorylation suggests that this sensor is a candidate for in
vivo studies of ERK signaling. However, our preliminary
experiments in NIH-3T3 cells indicated that EAS-3 was
susceptible to intracellular phosphatase activity (data not
shown). We surmise that this is due to the absence of a
protective phospho-specific binding domain within the
EAS-3 construct. Such binding domains have been crucial
in the development of other FRET-based signaling sensors
of kinase activity [2-4,6,7]. These binding domains, how-
ever, are taken from naturally occurring domains that are
specific for each target sequence. Unfortunately, no
known phospho-specific binding domain exists for Elk1
Determination of ERK2 specificity for EAS-3Figu e 4
Determination of ERK2 specificity for EAS-3. (A) Phosphorylation of EAS-3 is efficient with pERK2, but not pp38 or 
pSAPK. pp38 and pSAPK incorporates little or no 32P into EAS-3 at the same relative specific activity as pERK2. Band intensities 
were quantitated by densitometry and are shown graphically. Equal protein loading of EAS-3 is shown by Coomassie staining. 
(B) Specific targets for pERK2 (MBP), pp38 (GST-ATF2), and pSAPK (GST-cJun) are efficiently phosphorylated in the presence 
of γ-[32P]ATP. The amounts of active kinase used in A were based on the relative incorporation of 32P into each cognate sub-
strate by the respective kinase. (C) Fluorimetry of EAS-3 with MAPKs shows that the FRET efficiency change is significantly 
diminished in the presence of pp38 or pSAPK as compared to pERK2. This is consistent with the phosphorylation assay in A.
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BMC Chemical Biology 2005, 5:1 http://www.biomedcentral.com/1472-6769/5/1in the region of Ser383/389. Therefore, we are using a
semi-rational approach to develop a phospho-specific
binding domain that acts to protect the phosphorylated
EAS-3 linker from intracellular phosphatases. This will
enable us to adapt the EAS-3 sensor for use in live cells.
Conclusion
These results show that our novel ERK Activity Sensors
provide real-time in vitro detection of MAP kinase activity.
This method can be applied to studying kinetics of ERK
activity in real time, as well as detection of ERK activity in
unknown cell lysate fractions. There is also the potential
to use these sensors for high-throughput screening of ERK
kinase activity with fluorescence plate readers. This
method is more direct and convenient to monitor ERK
activation in vitro than conventional assays that either use
radioactivity for detection or rely on indirect detection
using phospho-specific antibodies for MAPK targets.
Methods
EAS constructs
DNA coding for peptide linkers was amplified by PCR
with primers designed with Bgl II and BamHI sites at the
5' and 3' ends, respectively. The products were cloned into
pECFP-C1 (Clontech), and EYFP from pEYFP-N1 was sub-
sequently cloned in frame to create EAS constructs. EAS's
were cloned into pGEX-2T (Amersham) in frame with
GST for expression and purification purposes. These GST-
tagged constructs were used for initial fluorimetry
experiment of EAS constructs. Other versions of EAS's
were constructed using ECFP and EYFP with mutation
A(207,487)K, which eliminates dimerization of GFPs,
and cloned into pET21a (Novagen) with a Histidine-10
tag. These His10-tagged constructs were used for mutant
and specificity experiments. EAS-3 linker mutants were
made by Quickchange Site Directed Mutagenesis (Strata-
gene) to make either single or double point mutation
within the peptide linker. For expression in NIH-3T3 cells,
EAS's were cloned into the pECFP vector backbone with-
out tags.
EAS and active kinase expression
BL21(DE3) cells were transformed with EAS constructs
and plated on LB agar supplemented with 100 µg/ml
ampicillin. Colonies were picked into 4 ml LB-Amp and
shaken overnight at 30°C. 250 ml LB was inoculated with
starter culture, grown to A600 of 0.6, and induced with 0.1
mM IPTG for 18 hours. Cells were spun down, lysed by
french press, and cell fragments were spun down at
18,000 rpm in a Beckman JA-20 rotor for 30 min. Proteins
were purified from lysates over Ni-NTA Superflow (Qia-
gen) or Glutathione Sepharose 4B (Amersham).
Activated kinases were purified as described [19]. pERK2
was either purchased (NEB) or purified from bacteria
transformed with a plasmid containing both constitu-
tively active MEK1* and His-tagged ERK2. Phosphoryla-
tion of ERK2 by MEK1* occurred in bacteria prior to lysis.
BL21(DE3) cells were electroporated with MEK1*/ERK2
construct and grown overnight at 37°C on LB-Amp agar
plates. Several colonies were picked and incubated in 4 ml
of TB supplemented with 100 µg/ml carbenicillin. The
starter culture was added to 1L of TB, grown to A600 of
0.35, and then induced with 0.25 mM IPTG for 12 hours
at 30°C. Cells were harvested and lysed as above, and
purified over Ni-NTA Superflow. Activated p38 and SAPK/
JNK were purified from bacteria electroporated with two
plasmids, one coding for constitutively active MEK kinase
4 (MEKK4*) and another coding for MEK4 and either His-
tagged p38 or His-tagged SAPK/JNK. These constructs
were grown and purified as above, except with both carbe-
nicillin and kanamycin (50 µg/ml). Protein concentration
and buffer exchange performed with Centriplus, Centri-
con, and Microcon ultrafiltration membranes (Millipore).
Kinase assays and fluorimetry
Radioactive kinase assays were performed in 25 µl in 12.5
mM MOPS pH 7.5, 12.5 mM β-glycerophosphate pH 7.3,
7.5 mM MgCl2, 500 µM NaOrthovanadate, 500 µM NaF,
and 9.7 nM DTT. Amounts of kinase and substrate added
to reactions are indicated in figure legends. Finally, ATP
supplemented with 0.2 nmol [γ-32P]ATP (6000 mCi/
mmol, Molecular Bioproducts), was added to a final con-
centration of 1 mM. Reactions were incubated at 30°C for
15 minutes, 8.3 µl of 4× protein sample buffer (SB) were
added, and samples were boiled for 5 minutes. Samples
were analyzed with 10% or 12% SDS-PAGE (BioRad
Mini-Protean II) and transferred to a nitrocellulose mem-
brane. The membrane exposed to a phosphoscreen and
scanned on a Storm 860 (Molecular Dynamics). Quanti-
tative densitometry of bands was performed using Image-
Quant 5.0 (Molecular Dynamics).
Fluorimetry performed in a Shimadzu Spectrofluoropho-
tometer RF-5301PC. Assays were performed in same
buffer as above in a volume of 2.5 ml. The final concen-
tration of EAS constructs was 250 nM and final concentra-
tion of pERK2 was 50 nM. The reaction was incubated in
fluorimeter and warmed to 30°C. Excitation was set at
425 nm to excite ECFP and avoid excitation of EYFP and
readings were taken in 0.2 nm increments. An initial read-
ing was taken prior to ATP addition. To initiate reaction,
ATP was added to a final concentration of 1 µM, a spinner
was activated for 1 minute, and first reading taken at 2
minutes. EYFP to ECFP ratios were calculated by dividing
EYFP peak emission by ECFP peak emission. Peak emis-
sions were defined as an average intensity of EYFP
between 524.6–525.4 nm and of ECFP between 474.6–
475.4 nm.Page 7 of 8
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